Firefly Neuroscience Faces Liquidity Doubts Amid AI Brain Health Push

TL;DR

**AIFF's cutting-edge brain tech is exciting, but the going concern warning means this stock is a high-risk gamble on future funding.**

AI Summary

Firefly Neuroscience, Inc. (AIFF) is an artificial intelligence company focused on precision neuroscience, utilizing AI and electrophysiological data to enhance clinical decision-making for brain health. The company has developed the Firefly Platform, a vertically integrated hardware, software, and data infrastructure that captures and analyzes EEG and ERP assessments. This platform aims to provide clinicians with objective insights into brain function, addressing the perceived under-measurement of the brain in medicine. The company's strategy involves expanding its network to increase data depth and diversity, thereby enriching its proprietary database. AIFF's financial health, however, faces significant liquidity risks, raising substantial doubt about its ability to continue as a going concern. The company's market value of non-affiliate common stock was approximately $31,304,976 as of June 30, 2025, with 14,793,075 shares outstanding as of March 25, 2026. The company also highlights the complexity of regulatory landscapes and the need for successful commercialization to achieve profitability.

Why It Matters

Firefly Neuroscience's innovative AI-driven platform for brain health could revolutionize diagnostics, offering more objective data for conditions like ADHD and PTSD. However, the significant liquidity risks highlighted in the 10-K filing cast a long shadow over its potential, directly impacting investor confidence and the company's ability to fund crucial R&D and commercialization efforts. For employees, this raises job security concerns, while customers might face uncertainty regarding long-term product support. In a competitive neuroscience market, financial instability could severely hinder AIFF's ability to compete with larger, more established medical device and diagnostic companies.

Risk Assessment

Risk Level: high — The filing explicitly states, "We are facing significant liquidity risks that raise substantial doubt about our ability to continue as a going concern." This direct statement, found in the 'Summary of Risk Factors,' indicates a fundamental financial instability. Furthermore, the company's dependence on obtaining sufficient funding to conduct planned operations and realize potential profits, as noted in the forward-looking statements, underscores its precarious financial position.

Analyst Insight

Investors should approach AIFF with extreme caution due to the explicit 'going concern' warning. Await further financial disclosures demonstrating a clear path to sustained funding and profitability before considering any investment, as the current risks are substantial.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Revenue Breakdown

Key Numbers

• $31.3M — Market Value of Non-Affiliate Common Stock (As of June 30, 2025, indicating current market valuation for public float.)
• 14.8M — Common Stock Shares Outstanding (As of March 25, 2026, representing the total shares available.)
• 0.1040 — Exchange Ratio (Ratio for WaveDancer Common Stock to Firefly Common Stock conversion during the Merger.)
• $0.0001 — Common Stock Par Value (Per share par value for Firefly Neuroscience, Inc. Common Stock.)
• 504,324 — Pre-Funded Warrants (Aggregate shares purchasable by PIPE Investors at $0.0001 exercise price.)
• 823,530 — Warrants (Aggregate shares purchasable by PIPE Investors at $0.71 exercise price.)

Key Players & Entities

• FIREFLY NEUROSCIENCE, INC. (company) — Registrant
• Nasdaq Capital Market (regulator) — Exchange for Common Stock
• U.S. Securities and Exchange Commission (regulator) — Filing authority
• Helena Special Opportunities LLC (company) — Affiliate of Helena Partners Inc.
• Evoke Neuroscience Inc. (company) — Company related to Evoke System
• WaveDancer, Inc. (company) — Former name of Firefly Neuroscience, Inc. prior to Merger
• $31,304,976 (dollar_amount) — Aggregate market value of non-affiliate common stock as of June 30, 2025
• 14,793,075 (dollar_amount) — Shares of Common Stock outstanding as of March 25, 2026
• August 12, 2024 (date) — Merger Closing Date
• December 31, 2025 (date) — Fiscal year ended

FAQ

Risk Factors

• Substantial Doubt About Going Concern [high — financial]: The company's financial condition raises substantial doubt about its ability to continue as a going concern. This is primarily due to ongoing operating losses and the need for future financing to fund operations.
• Commercialization and Adoption Risk [high — market]: Successful commercialization of the Firefly Platform is critical for profitability. The company faces the challenge of gaining widespread adoption by clinicians and integrating its technology into existing healthcare workflows.
• Complex Regulatory Landscape [medium — regulatory]: Navigating the complex regulatory landscape for medical devices and AI in healthcare presents a significant risk. The company's FDA-510(k) clearance for the Evoke System is a positive step, but ongoing compliance and potential future regulatory changes pose challenges.
• Data Security and Privacy [medium — operational]: As an AI company handling sensitive electrophysiological data, Firefly Neuroscience faces risks related to cybersecurity and patient data privacy. Breaches or non-compliance with data protection regulations could lead to significant financial and reputational damage.
• Competition and Technological Advancements [medium — market]: The neuroscience and AI healthcare market is competitive. The company must continuously innovate and differentiate its Firefly Platform to stay ahead of competitors and adapt to rapid technological advancements.
• Dependence on Future Financing [high — financial]: The company's ability to fund its operations and growth initiatives is dependent on its ability to secure future financing. Failure to obtain necessary capital could impede its ability to execute its business plan.

Industry Context

Firefly Neuroscience operates in the rapidly evolving field of precision neuroscience, leveraging artificial intelligence and electrophysiological data. The industry is characterized by a growing demand for objective diagnostic tools for brain health conditions, moving beyond subjective assessments. Key trends include the integration of AI in medical diagnostics, the increasing importance of big data in healthcare, and the development of non-invasive monitoring technologies.

Regulatory Implications

The company's operations are subject to stringent healthcare regulations, including FDA oversight for its medical devices. Achieving and maintaining regulatory compliance, particularly with evolving AI in healthcare guidelines, is critical. The FDA-510(k) clearance for the Evoke System is a significant milestone, but ongoing adherence to quality system regulations and data privacy laws (like HIPAA) is essential for continued market access and trust.

What Investors Should Do

1. Monitor cash burn and future financing rounds.
2. Evaluate the pace of clinical site adoption and revenue growth.
3. Assess the competitive landscape and technological differentiation.
4. Review updates on regulatory compliance and data security measures.

Key Dates

• 2025-12-31: Evoke System in active use — Indicates commercial deployment and market penetration of the company's core product.
• 2025-06-30: Market Value of Non-Affiliate Common Stock — Provides a snapshot of the company's public market valuation at approximately $31.3 million.
• 2026-03-25: Common Stock Shares Outstanding — States the total number of shares outstanding as 14.8 million, relevant for per-share calculations and ownership.

Glossary

Firefly Platform

A vertically integrated hardware, software, and data infrastructure developed by Firefly Neuroscience to capture, analyze, and report on electrophysiological data (EEG and ERP) for brain health assessments. (This is the company's core technology offering, central to its business model and value proposition.)

EEG (Electroencephalography)

A non-invasive method to record electrical activity of the brain, typically using electrodes placed on the scalp. (A primary data source the Firefly Platform utilizes for analysis.)

ERP (Event-Related Potential)

A measured brain response that is the result of a specific sensory, cognitive, or motor event. (Another key type of electrophysiological data analyzed by the Firefly Platform to provide insights into brain function.)

Firefly Flywheel

The company's concept describing the compounding relationship between clinical deployment, data acquisition, and report quality, where each assessment generates revenue and enriches the proprietary database. (Explains the company's strategy for data network effects and sustainable growth.)

FDA-510(k) clearance

A process by which the U.S. Food and Drug Administration (FDA) determines that a proposed medical device is substantially equivalent to a legally marketed device. (Indicates regulatory approval for the Evoke System, a crucial step for commercialization in the US.)

Going Concern

An accounting principle that assumes a company will continue to operate for the foreseeable future. A 'going concern' notice indicates substantial doubt about this assumption. (Highlights significant financial distress and uncertainty about the company's ability to survive.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available in the provided text excerpt. The filing focuses on the current state of the business, its technology, risks, and financial condition as of the reporting period, including the significant going concern warning.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share AIFF Nasdaq Capital Marke
• $0.71 — of Common Stock at an exercise price of $0.71 per share, issued to the PIPE investors

Filing Documents

• aiff20251231_10k.htm (10-K) — 3156KB
• ex_930821.htm (EX-4.1) — 27KB
• ex_935985.htm (EX-14.1) — 49KB
• ex_939322.htm (EX-23.1) — 2KB
• ex_904624.htm (EX-31.1) — 15KB
• ex_904625.htm (EX-31.2) — 13KB
• ex_904626.htm (EX-32.1) — 6KB
• ex_904627.htm (EX-32.2) — 6KB
• fireflybargraph.jpg (GRAPHIC) — 33KB
• image01.jpg (GRAPHIC) — 19KB
• image02.jpg (GRAPHIC) — 18KB
• image04.jpg (GRAPHIC) — 24KB
• image05.jpg (GRAPHIC) — 20KB
• 0001437749-26-010500.txt ( ) — 13460KB
• aiff-20251231.xsd (EX-101.SCH) — 101KB
• aiff-20251231_cal.xml (EX-101.CAL) — 79KB
• aiff-20251231_def.xml (EX-101.DEF) — 731KB
• aiff-20251231_lab.xml (EX-101.LAB) — 608KB
• aiff-20251231_pre.xml (EX-101.PRE) — 784KB
• aiff20251231_10k_htm.xml (XML) — 2145KB

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 20 Item 1B. Unresolved Staff Comments 47 Item 1C. Cybersecurity 47 Item 2.

Properties

Properties 48 Item 3.

Legal Proceedings

Legal Proceedings 48 Item 4. Mine Safety Disclosures 48 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 49 Item 6. [Reserved] 50 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 50 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 61 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 61 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure. 61 Item 9A.

Controls and Procedures

Controls and Procedures 61 Item 9B. Other Information 62 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 62 PART III Item 10. Directors, Executive Officers and Corporate Governance 63 Item 11.

Executive Compensation

Executive Compensation 67 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 79 Item 13. Certain Relationships and Related Transactions, and Director Independence 81 Item 14. Principal Accountant Fees and Services 85 PART IV Item 15. Exhibit and Financial Statement Schedules 86 Item 16. Form 10-K Summary 91

Signatures

Signatures 92 Table of Contents INTRODUCTORY NOTES Use of Terms "2024 Plan" means the Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan, as amended by Amendment No.1 to the Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan. "ADHD" means Attention-Deficit/Hyperactivity Disorder "AI" means artificial intelligence. "Arena" refers to Arena Business Solutions Global SPC II, Ltd, an exempted company limited by shares incorporated under the laws of the Cayman Islands. "Board" means the Board of Directors of Firefly. "Broker Warrants" means the warrants to purchase shares of Common Stock issued to certain brokers as compensation in connection with certain transactions consummated prior to the Merger. "Bylaws" means the Amended and Restated Bylaws of Firefly Neuroscience, Inc. "Charter" means the Amended and Restated Certificate of Incorporation of Firefly Neuroscience, Inc., as amended from time to time. "Common Stock" means the shares of common stock of Firefly Neuroscience, Inc., par value $0.0001 per share. "December 2024 Purchase Agreement" means that certain Securities Purchase Agreement, dated as of December 20, 2024, between the Company and Helena. "EEG" means electroencephalograms. "Effectiveness Date" means February 6, 2024, the date on which the SEC declared the registration statement on Form S-4 (File No. 333-276649) effective. "Evoke" means Evoke Neuroscience Inc. "Evoke System" means our FDA-510(k) cleared EEG and ERP acquisition hardware "Exchange Act" means the U.S. Securities Exchange Act of 1934, as amended. "Exchange Ratio" means 0.1040, the ratio in which the shares of WaveDancer Common Stock were converted to shares of Firefly Common Stock. "FDA" means the U.S. Food and Drug Administration. "FD&C Act" means the Federal Food, Drug, and Cosmetic Act "Firefly" means Firefly Neuroscience, Inc., a Delaware corporation (formerly known as WaveDancer, Inc. prior to the consummation of the Merger). "Firefly System" mean

BUSINESS

ITEM 1. BUSINESS. Overview Firefly Neuroscience, Inc. is an artificial intelligence company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient's brain is functioning. Firefly Neuroscience, Inc. is rebuilding the foundation of how electrophysiological data flows into clinical decision-making for brain health. We believe the brain is the most under-measured organ in medicine, and that the tools to change this have, until now, been inaccessible to the clinicians who need them most. We have built the Firefly Platform: a vertically integrated hardware, software, and data infrastructure that captures standardized electroencephalographic (EEG) and event-related potential (ERP) assessments at the point of care, analyzes that data through our proprietary analytics engine, and delivers structured, clinician-ready reports back to the provider, all within a single seamless workflow. Every scan expands and enriches our database. Every clinic that joins our network increases the depth and diversity of our data. We describe this compounding relationship between clinical deployment, data acquisition, and report quality as the Firefly Flywheel. Our FDA-510(k) cleared Evoke System, commercially deployed as the Evoke System, is in active use across more than 85 clinical sites in the United States as of December 31, 2025. Clinicians use the system to perform EEG and ERP assessments, which are analyzed by our cloud-based platform and returned as structured reports designed to support clinical decision-making. Our subscription-based commercial model creates a recurring revenue stream that scales in lockstep with clinical utilization, meaning that the more deeply clinicians integrate electrophysiological assessment into their practice, the more revenue we generate and the more our database grows. Figure 1: The Firefly Flywheel — each clinical assessment simultane

View Full Filing

View this 10-K filing on SEC EDGAR